The intended audience for this activity is endocrinologist fellows and early-career clinicians treating patients with type 1 diabetes.
Rodolfo Galindo, MD - Program Chair
University of Miami
Davida F. Kruger, MSN, APN-BC, BC-ADM - Program Chair, Emeritus
Henry Ford Health
Carol Wysham, MD
Rockwood Clinic PS
Elizabeth R. Seaquist, MD
University of Minnesota Medical School
Irl B. Hirsch, MD, MACP
University of Washington School of Medicine
Janet B. McGill, MD
Washington University School of Medicine
LLorena Alarcon-Casas Wright, MD
University of Washington School of Medicine
Luisa A. Duran, MD
John Muir Health
Jill Weissberg-Benchell, Ph.D, CDCES
Northwestern University Feinberg School of Medicine
Anne Peters, MD
University of Southern California
Mark A. Atkinson, Ph.D
University of Florida, Departments of Pathology and Pediatrics
Robert Eckel, MD
University of Colorado Anschutz Medical Campus
Camille E. Powe, MD
Harvard Medical School
Faisal Malik, MD
University of Washington
STATEMENT OF INDEPENDENCE
As a provider of CME accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society’s guideline task force.
DISCLOSURE POLICY
The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion. The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.
The Endocrine Society has reviewed these relationships to determine which are relevant to the content of this activity and resolved any identified conflicts of interest for these individuals.
The faculty reported the following relevant financial relationship(s) during the content development process for this activity:
Rodolfo J. Galindo, MD (Co-chair) was partially supported in part by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH). He has received research grants/support from Novo Nordisk, Eli Lilly, Boehringer and Dexcom, and consulting/advisory/honoraria from Abbott Diabetes, Boehringer, Dexcom, Eli Lilly, Novo Nordisk (within the last 24 months).
Davida F. Kruger MSN, APN-BC, BC-ADM (Co-chair) serves on the Advisory board for Abbott, Dexcom, Eli Lilly and Company, Pendulum, Insulet, Novo Nordisk, Sanofi Aventis, Embecta, Arecore Limited, MannKind and Medtronic. She is part of the Speakers Bureau for Abbot, Lilly, Insulet, Dexcom and Novo Nordisk; and receives grants from Abbott, Novo Nordisk, Helmsley Foundation, Tandem and Insulet.
Carol Wysham, MD has served as an investigator for Corcept, Eli Lilly & Company, Novo Nordisk, and Vanda; and has served on the advisory board for Novo Nordisk, CeQur and Abbott.
Elizabeth Seaquist, MD has served on the Eli Lilly Global Diabetes Care Advisory Board, the NIDDK Advisory Committee and the External Advisory Committee for the University of Michigan Caswell Diabetes Center; has been a consultant for Zucara Therapeutics; is a member of the International Hypoglycemia Study Group; and received grants from the NIH and JDRF.
Irl B. Hirsch, MD has served as a consultant for Abbott Laboratories, Lifescan, Eembecta, and GWave; and received grant funding from Dexcom and Insulet Corporation.
Janet B. McGill, MD, MA, FACE has served as a consultant for Boehringer Ingelheim and Mannkind; and received grant funding from Novo Nordisk and JDRF.
Anne Peters, MD has served on an advisory board for Abbott Diabetes Care, Medscape, Novo Nordisk, Vertex, and Zealand; has served as a consultant for Blue Circle Health; has received research support from Dexcom, Insulet, Abbott Diabetes Care; and has stock with Omada Health
Mark Atkinson, PhD has served as a board member for Diamyd Medical; and has been a medical advisor for Quell Rx, Sanofi, Provention Bio, Endsulin, Vertex Pharmaceuticals and Novo Nordisk
Robert Eckel, MD is a scientific consultant for Sanofi Aventis and Regeneron Pharmaceuticals and has serves as a scientific advisor for Merk, Novo Nordisk and Amgen. He has served on the advisory board for Amgen, Arrowhead, Better Co., 89bio, Novo Nordisk, Precision BioSciences, the Healthy Aging Co., Tolmar, UpToDate and Weight Watchers.
Camille Powe, MD serves as consultant for Mediflix, Inc; is a Pregnancy and Reproductive Health Interest Group Chair and Associate Editor for the American Diabetes Association; a journal section editor for Current Diabetes Reports; and receives grants from NIH/NIDDK, NIH/NICHD, K23, U01, R01, and the Robert Wood Johnson Foundation Harold Amos Faculty Development Program
The following faculty reported no relevant financial relationships: Jill A. Weissberg-Benchell, PhD, CDCES; Faisal S. Malik, MD, MSHS; Luisa A. Duran, MD; Lorena Alarcon-Casas Wright, MD.